Clinical Trial Detail

This clinical trial studies rituximab in treating patients undergoing donor peripheral blood stem cell transplant for relapsed or refractory B-cell lymphoma. Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cell-killing substances to them. Giving rituximab before and after donor peripheral blood stem cell transplant may kill more cancer cells and may help the patient's immune system from rejecting the donor's stem cells

Genders Eligible for Study: Both

Accepts Healthy Volunteers: No

- A diagnosis of CD20-expressing B-cell malignancy of any histologic type or grade for whom non-myeloablative allogeneic transplant is considered an appropriate treatment option

- Enrolled on a non-myeloablative allogeneic HCT protocol employing total-body irradiation (TBI)-based conditioning of =< 4 Gy, with or without fludarabine; this protocol may be used as an adjunct to the allogeneic arm of a tandem autologous/allogeneic transplant protocol, provided the allogeneic conditioning meets the above criteria

- Receiving unmodified peripheral blood mononuclear cell graft products

- Patients with an appropriate related or unrelated donor; human leukocyte antigen (HLA)-haploidentical donors are excluded

- Able to give informed consent (if >= 18 years of age), or with a legal guardian capable of giving consent (if < 18 years of age)

Other eligibility criteria may apply.

- Ineligible for non-myeloablative allogeneic HCT

- Receiving an HLA-haploidentical allograft

- Are fertile but unwilling to use contraception during and for at least 12 months after HCT

- Females who are pregnant or breast-feeding

Other exclusion criteria may apply.